Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma

Completed · Phase 2

Conditions studied: Mantle Cell Lymphoma

In brief

rituximab and modified (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years

Key facts

Study ID

NCT00581854

Run by

University of Wisconsin, Madison

People needed

22

Starts

2000-06-01

Expected to finish

2010-03-01

Last updated by the study team

2019-12-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Untreated mantle cell lymphoma

You may not qualify if…

• Pregnant or breast feeding

Where it is running

• UWCCC — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.